Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Silver Trust (SLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Silver Trust — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while iShares Silver Trust trades at $52.7. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| ADPT | SLV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $105.57 |
52-Week Low | $10.24 | $33.00 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SLV, the iShares Silver Trust ETF, trades at $54.46, down 1.02% on the day, reflecting ongoing volatility in silver prices. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent news highlights silver's 50% decline from January peaks but potential for a rebound amid industrial demand and inflation hedging. Financial ratios are not applicable as this is a commodity ETF tracking physical silver.
The outlook for SLV hinges on silver's dual role as an industrial metal and inflation hedge, with risks including Federal Reserve policy shifts and geopolitical tensions. Analysts see potential for price recovery if macroeconomic conditions support precious metals, but near-term volatility remains high due to rate hike expectations and dollar strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
